Detalhe da pesquisa
1.
Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.
Gastroenterology
; 147(1): 132-142.e4, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24704719
2.
The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.
Hepatology
; 55(3): 749-58, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22006408
3.
Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin.
J Hepatol
; 57(1): 39-46, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22414766
4.
Prevalence and impact of occult hepatitis B infection in chronic hepatitis C patients treated with pegylated interferon and ribavirin.
J Med Virol
; 82(5): 747-54, 2010 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-20336715
5.
Non-invasive assessment of liver fibrosis progression in hepatitis C patients retreated for 96 weeks with antiviral therapy: a randomized study.
Liver Int
; 30(7): 1049-58, 2010 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-20492512
6.
Predicting efficacy and safety outcomes in patients with hepatitis C virus genotype 1 and persistently 'normal' alanine aminotransferase levels treated with peginterferon alpha-2a (40KD) plus ribavirin.
Liver Int
; 28(1): 61-71, 2008 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-17971091
7.
Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen - The ANRS CO20-CUPIC study.
Clin Res Hepatol Gastroenterol
; 39(4): 443-50, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25636238
8.
Chronic hepatitis B treatment initiation and modification patterns in five European countries: a 2-year longitudinal, non-interventional study.
Antivir Ther
; 19(3): 235-43, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-23574686
9.
Chronic hepatitis B monitoring and treatment patterns in five European countries with different access and reimbursement policies.
Antivir Ther
; 19(3): 245-57, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24343051
10.
Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results.
Antivir Ther
; 18(8): 1015-9, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23558093
11.
Performance of an antigen-antibody combined assay for hepatitis C virus testing without venipuncture.
J Clin Virol
; 55(3): 220-5, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22901327
12.
Pharmacological exposure to ribavirin: a key player in the complex network of factors implicated in virological response and anaemia in hepatitis C treatment.
Dig Liver Dis
; 43(11): 850-5, 2011 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-21596633
13.
Pegylated interferon-alpha-based treatment for chronic hepatitis C in renal transplant recipients: an open pilot study.
Transpl Int
; 22(5): 562-7, 2009 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-19175562
14.
Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
Gastroenterology
; 131(4): 1040-8, 2006 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-17030174